Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors-Reference-Cited by-同舟云学术

Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors

Published:2023-02-24 Issue:1 Volume:12 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Ding Jian¹,Guyette Sarah¹,Schrand Brett¹,Geirut Jessica¹,Horton Holly¹,Guo Guangwu¹,Delgoffe Greg²³,Menk Ashley²,Baeuerle Patrick A.¹,Hofmeister Robert¹,Tighe Robert⁴

Affiliation:

1. Research & Development, Formerly of TCR2 Therapeutics, Inc, Cambridge, MA, USA

2. Tumor Microenvironment Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA

3. Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA

4. Research & Development, TCR2 Therapeutics, Inc, Cambridge, MA, USA

Funder

TCR Therapeutics

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2023.2182058

Reference41 articles.

1. Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response

2. The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity

3. Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma

4. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

5. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineered T cells for Colorectal Cancer;Immunotherapy;2024-09-04

2. The potential of γδ CAR and TRuC T cells: An unearthed treasure;European Journal of Immunology;2024-08-27

3. Emerging New Targets in Systemic Therapy for Malignant Pleural Mesothelioma;Cancers;2024-03-22

4. Reprogramming of human γδ T cells by expression of an anti-CD19 TCR fusion construct (εTRuC) to enhance tumor killing;Journal of Leukocyte Biology;2023-12-27

5. Functional enhancement of mesothelin-targeted TRuC-T cells by a PD1-CD28 chimeric switch receptor;Cancer Immunology, Immunotherapy;2023-10-18